ContributionsofFastingandPostprandialGlucoseConcentrationstoHaemoglobinA1cinDrug-Na"ıveMal-GlucoseMetabolisminChinesePopulationUsingContinuousGlucoseMonitoringSystem

RengnaYan,1 YunHu,1 FengfeiLi,1 LanlanJiang,1 XiaohuaXu,1 JieWang,1 YingZhang,1 LeiYe,2 KokOnnLee,3 XiaofeiSu,1 andJianhuaMa1

1DepartmentofEndocrinology,NanjingFirstHospital,NanjingMedicalUniversity,Nanjing210012,China
2NationalHeartResearchInstituteSingapore,NationalHeartCentreSingapore,Singapore169609
3DepartmentofMedicine,NationalUniversityofSingapore,Singapore119228

Correspondence should be addressed to Xiaofei Su; suxiaofeifei@126.com and Jianhua Ma; majianhua196503@126.com

Received27August2019;Accepted29October2019;Published1December2019

AcademicEditor:PawelGrzmil

Copyright©2019RengnaYanetal.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,whichpermitsunrestricteduse,distribution,andreproductioninanymedium,providedtheoriginalworkisproperlycited.

Aim. To clarify the contributions of fasting glucose (FG) and postprandial glucose (PG) to HbA1c in drug-na"ıve patients with type 2 diabetes (T2D) and impaired glucose tolerate (IGT)/impaired fasting glucose (IFG). Methods. Continuous glucose monitoring (CGM) was performed in 305 drug-na"ıve Chinese patients with T2D or IGT/IFG. The incremental area under the curve (AUC) above a glucose value of 6.1mmol/L or FG glucose levels were calculated to evaluate the contributions of PG or FG to HbA1c values. Results. According to quintiles of HbA1c, T2D patients were divided into five groups (group 1 to 5), and patients with IGT/IFG were assigned into group 0. PG was the predominant contributor in the lower groups with HbA1c 4.9∼6.0% and 6.1∼7.8%. The relative contributions of FG and PG to HbA1c had no significance in the middle groups of HbA1c (7.9∼8.7% and 8.8∼9.5%). FG contributed significantly more than PG in the higher groups of HbA1c (9.6∼10.9% and 11.0∼14.6%). Regression analyses indicate that the contributions of FG and PG were equal (both 50%) when the level of HbA1c was 8.5%. Conclusions. In drug-na"ıve patients with T2D or IGT/IFG, PG contributed more in patients with HbA1c < 8.5%, whereas FG became the predominant contributor in the poorly controlled patients with HbA1c ≥ 8.5%. These results may help the health-care provider set appropriate plasma glucose testing goals with the expectation of achieving specific HbA1c values.

1.Introduction

Glycemic control is a cornerstone in delaying the onset and decreasing the incidence of both the short- and long-term complications of diabetes. Glycated haemoglobin (HbA1c) is a gold-standard parameter in evaluating the effectiveness of glycemic control in patients with diabetes [1]. The Diabetes Control and Complication Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) indicated that HbA1c > 7.0% is associated with a significantly increased risk of both microvascular and macrovascular complications, regardless of underlying treatment [2–5]. Fasting glucose (FG) and postprandial glucose (PG) are commonly used as daily makers to evaluate glycaemic control and modify therapeutic strategy. Clearly understanding the relationship between plasma glucose levels and HbA1c will help to set appropriate day-to-day plasma glucose testing goals for achieving the target HbA1c level. There is no consensus about the association between FG and PG with HbA1c in patients with type 2 diabetes (T2D) [6–14]. Most previous studies were based on multipoint glucose measurements in treated patients. In this study, we evaluate the contribution of FG and PG on HbA1c in newly diagnosed and untreated patients with T2D or IGT/IFG.
using continuous glucose monitoring systems (CGMS). This may help to target the better surrogate glycemic marker for achieving the target HbA1c level and for early detection of glycemic control status.

2. Materials and Methods

2.1. Subjects. According to 1999 WHO diagnostic criteria [15], DM was defined as fasting plasma glucose ≥7.0 mmol/L and/or 2h PG ≥11.1 mmol/L. Impaired Glucose Tolerance (IGT) was defined as fasting plasma glucose <7.0 mmol/L and 2h PG ≥7.8 mmol/L. Impaired Fasting Glycaemia (IFG) was defined as fasting plasma glucose ≥6.1 to <7.0 and 2h PG <7.8 mmol/L. A total of 305 newly diagnosed, drug-naïve patients with T2D or IGT/IFG were recruited between January 2015 and December 2018 in Nanjing First Hospital, Nanjing Medical University, China. The inclusion criteria were newly diagnosed, drug-naïve patients with T2D or IGT/IFG. Patients who had ketoacidosis, impaired renal function (serum creatinine >1.5 mg/dl or liver (aspartate aminotransferase or alanine aminotransferase 2.5 times the upper limit of the normal range) or liver (aspartate aminotransferase or alanine aminotransferase 2.5 times the upper limit of the normal range) or a history of anaemia, or suffered from cancer were excluded. The study was approved by the ethics committee of Nanjing Hospital. Informed consents were signed by all patients. The methods were conducted in accordance with the Declaration of Helsinki guidelines, including any relevant details.

2.2. Clinical and Laboratory Assessments. After admission, detailed interviews and regular laboratory analyses were performed in all patients. Anthropometric parameters of height, weight, waist circumference, hip circumference, and blood pressure were measured, and recorded BMI was calculated as body weight divided by height squared (kg/m²). HbA1c was analyzed using high-performance liquid chromatography (Bio-Rad, USA). Serum creatinine, liver functional parameters (aspartate aminotransferase and alanine aminotransferase), and lipid profiles (total cholesterol, triglycerides, high- and low-density lipoproteins) were measured by enzymatic assays (Olympus AU5400 autoanalyzer; Beckman Coulter, Japan).

2.3. Food Intake. All subjects were instructed to maintain physical activity according to their doctors' personalized instructions and received meals consisting of a total daily caloric intake of 25 kcal/kg/day. The ratio of carbohydrate, proteins, and fats were 55%, 17%, and 28%, respectively. Patients were instructed to have breakfast, lunch, and dinner at 7:00 AM, 11:00 AM, and 5:00 PM, respectively.

2.4. Calculation of the Relative Contributions of PG and FG to A1c Levels. A retrospective CGMS (Sofsensor, CGMS-Gold, Medtronic Incorporated, Northridge, USA) [16] was applied to the recruited patients 72 hours before glycemic control treatment. To minimize the influence of diet taken before hospital admission, the contributions of FG and PG to overall hyperglycaemia was calculated using CGMS data obtained in the second 24 hours (24 h) after admission. Blood glucose level >6.1 mmol/L is considered as hyperglycemia. We defined the glucose area under the curve (AUC) above 6.1 mmol/L during the second 24-h interval as AUCtotal to represent overall hyperglycaemia [13]. The glucose AUC above FG was defined as AUCFG, reflecting the contribution of PG to overall hyperglycaemia during 24h. The AUCPG was defined as AUCtotal − AUCFG. The relative contributions of FG and PG to overall hyperglycaemia were calculated as [(AUCtotal − AUCPG)/ AUCtotal] × 100% and (AUCPG/AUCtotal) × 100%, respectively [14]. The HbA1c values used for analysis in this study were those obtained at admission. According to quintiles of HbA1c, the subjects with diabetes were divided into five groups (from 1 to 5) and patients with IGT/IFG were allocated into group 0 to evaluate the contribution of FG and PG to glucose increments.

2.5. Statistical Analysis. All statistical analyses were performed using the SPSS statistical program, version 16.0 (SPSS, Chicago, IL, USA). The data are shown as mean ± SD or percentage. Parameters of AUC and other relative clinic data were compared over groups of HbA1c using one-way ANOVA, followed by Bonferroni's test. Relative contributions of FG and PG were compared using a paired Student’s t test. P < 0.05 was considered significant.

3. Results

The clinical characteristics and demographics of subjects with prediabetes and diabetes according to the quintiles of HbA1c are shown in Table 1. A total of 305 patients (208 men and 97 women) with newly diagnosed T2D or IGT/IFG were recruited. Their mean age was 51.1 ± 11.4 years, mean body mass index (BMI) was 25.3 ± 3.5 kg/m², and mean HbA1c was 9.3 ± 1.9% (range 4.9–14.6%).

All the AUC results calculated from CGM are indicated in Table 1 and Figure 1. The level of FG, the overall hyperglycaemia (AUCtotal), and fasting glucose increments (AUCFG) were increased from the lowest to the highest groups of HbA1c, especially in the higher groups. However, AUCPG, which reflects postprandial glucose increments, almost remained stable over the higher groups. In the lowest group, IGT/IFG group, AUCFG and AUCPG were both smallest. In lower group 1, AUCPG was slightly above AUCFG. In quintiles 2 and 3, AUCPG was higher than AUCFG with the difference of 1.0 and 0.5 mmol/L/day, respectively. In the higher quintiles 4 and 5, the difference between AUCFG and AUCPG increased to 2.0 and 2.2 mmol/L/day, respectively.

The relative contribution of FG and PG is shown in Figure 2. PG contributed to hyperglycaemia more than FG in the lowest HbA1c groups (range: 4.9–6.0%, mean: 5.5 ± 0.4% and range: 6.1–7.8%, mean: 7.3 ± 0.5%). FG and PG equally contributed to hyperglycaemia in groups 2 and 3 (range: 7.9–8.7%, mean: 8.3 ± 0.3% and range: 8.8–9.5%, mean: 9.1 ± 0.2%). In the highest HbA1c quintiles 4 and 5 (range: 9.6–10.9%, mean: 10.1 ± 0.4% and range: 11.0–14.6%, mean: 12.1 ± 0.9%), fasting hyperglycaemia began to play a major role in the contribution to hyperglycaemia.
Table 1: Characteristics of all prediabetes and T2D patients over groups of HbA1c.

| HbA1c Groups | IGT/IFG | Quintiles of glycated haemoglobin in T2D patients | Total |
|--------------|---------|--------------------------------------------------|-------|
| Number       | 10      | 20                                               | 305   |
| Age (yrs)    | 41.1±19.4 | 53.2±10.9*                                         |       |
| Sex (M/F)    | 5/5     | 42/19                                             |       |
| Body mass index (kg/m²) | 28.4±8.3 | 25.7±3.1                                           |       |
| Haemoglobin (g/L) | 137.3±13.9 | 142.9±16.9                                        |       |
| Fasting glucose (mmol/L) | 5.6±0.9 | 7.8±1.8*                                         |       |
| AUC total (mmol/L-day) | 0.57±0.45 | 3.35±1.84*                                      |       |
| AUC PG (mmol/L-day) | 0.20±0.25 | 1.61±1.49*                                      |       |
| AUC FG (mmol/L-day) | 0.43±0.43 | 1.78±1.12*                                      |       |
| FG contribution (%) | 7.73±14.69 | 39.71±28.06*                                      |       |
| PG contribution (%) | 92.27±24.27 | 60.29±28.06*                                      |       |
| Mean glycated haemoglobin (%) | 5.5±0.4 | 7.3±0.5*                                        |       |
| Range of glycated haemoglobin (%) | 4.9–6.0 | 6.1–7.8                                         |       |

Data are mean ± SD. *Significant differences from the lower quintile.

Figure 1: Area under the glucose curve derived from continuous glucose monitoring over groups of HbA1c. *Significant differences from group 1. #Significant differences from the lower one group.

Area under the glucose curve (AUC)PG = AUCtotal - AUCFG.

As shown in Figure 3, the relative contribution of FG had obviously positive correlation with HbA1c. On the contrary, the relative contribution of PG was decreasing with increase in HbA1c. The regression analysis between the contribution of FG or PG and HbA1c showed that the two regression curves jointed at the point of HbA1c = 8.5%, suggesting that FG contributes more than PG from HbA1c > 8.5% and PG contributes less than PG when HbA1c < 8.5%.

4. Discussion

The present study indicates that in newly diagnosed, drug-naïve T2D or IGT/IFG, FG had dominant contribution to poorly controlled patients with HbA1c > 8.5%. Also, PG contributed more when HbA1c < 8.5%.

AUC_FG significantly increased from group 0 to 5, especially in the upper groups, whereas AUC_PG almost remained stable. It suggested that fasting hyperglycemia in the patients with higher HbA1c was the rising tide that would lift the postprandial hyperglycemia boat. When the fasting hyperglycemia decreased, the PG levels would drop down with the tide. Therefore, to eradicate hyperglycemia in poorly controlled patients with type 2 diabetes, the main principle of pharmacological intervention should be to choose therapeutic agents with an action primarily on basal glucose excursions. Although a recent review showed that PG strongly correlates with HbA1c or contributes
significantly to overall glycemic control [17], FG should not be ignored when it comes to the management of patients with T2D. FG was also found to be more important than PG in diagnosed T2D treated by antihyperglycemic drugs with HbA1c ≥ 9.3% [6].

PG excursions in combination with FG play an important role in the contribution to overall hyperglycemia. Postprandial glucose was a strong predictor of cardiovascular events and all-cause mortality in a long-term follow-up [18]. Here, we found that the contribution of PG to overall hyperglycemia was higher than that of FG, when HbA1c ranged from 4.9% to 6.0% (mean: 5.5 ± 0.4%) in IGT/IFG patients and ranged from 6.1% to 7.8% (mean: 7.3 ± 0.5%) in patients with diabetes. Previous studies reported that mild hyperglycemia with HbA1c < 7.3% or 7% or between 6.5 and 6.9% inclusive was mainly attributed to the elevation of PG [6, 19, 20]. All of these published studies suggested that the therapeutic measures of patients with mild hyperglycemia should be aimed at reducing postmeal glucose.

Kang et al. [19] performed CGMS in 59 newly diagnosed, drug-naive patients with T2D patients and found that the contribution of PG was 57.78% which was significantly higher than FG when HbA1c ≤ 7%, whereas the contribution of FG was 79.58% significantly higher than PG when HbA1c > 9%, and the contribution of FG and PG was equal with HbA1c between 7 and 9%. However, the study sample was small. Here, in a larger population, we found similar association between the contribution of FG and PG and HbA1c. More importantly, we showed that PG contributes more than PG from HbA1c > 8.5% and FG contributes less than PG when HbA1c < 8.5%, providing a cut point for reference in clinical treatment.

In conclusion, our results indicate that in drug-naive, Chinese patients with T2D or IGT/IFG, from mild to severe hyperglycemia, the predominant contribution to HbA1c changed from PG to FG with the changing point at HbA1c = 8.5%. This finding may aid doctors in formulating effective therapeutic plans according to the level of HbA1c.

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Disclosure**

Rengna Yan, Yun Hu, and Fengfei Li are the co-first authors.

**Conflicts of Interest**

The authors declare no conflicts of interest.

**Authors’ Contributions**

JHM, XFS, KOL, and LY conceived and designed the experiments. XHX and YZ performed the experiments. RNY analyzed the data. YH, FFL, LLJ, and JW contributed reagents/materials/analysis tools. RNY wrote the paper.

**Acknowledgments**

This study was supported by National Key R&D Program of China (no. 2018YFC1314102) and Jiangsu Provincial Special Program of Medical Science (BL2014010).

**References**

[1] American Diabetes Association, “Standards of medical care in diabetes-2009,” *Diabetes Care*, vol. 32, no. 1, pp. S13–S61, 2009.

[2] UK Prospective Diabetes Study (UKPDS) Group, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33),” *The Lancet*, vol. 352, no. 9131, pp. 837–853, 1998.

[3] The Diabetes Control and Complications Trial Research Group, “The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial,” *Diabetes*, vol. 44, no. 8, pp. 968–983, 1995.

[4] S. A. Imran, R. Rabasa-Lhoret, and S. Ross, “Targets for glycemic control,” *Canadian Journal of Diabetes*, vol. 37, no. 1, pp. S394–S397, 2013.

[5] I. M. Stratton, A. I. Adler, H. A. Neil et al., “Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study,” *BMJ*, vol. 321, no. 7258, pp. 405–412, 2000.

[6] L. Monnier, H. Lapinski, and C. Colette, “Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c,” *Diabetes Care*, vol. 26, no. 3, pp. 881–885, 2003.

[7] H. Shimizu, Y. Uehara, S. Okada, and M. Mori, “Contribution of fasting and postprandial hyperglycemia to hemoglobin A1c in insulin-treated Japanese diabetic patients,” *Endocrine Journal*, vol. 55, no. 4, pp. 753–756, 2008.

[8] H. J. Woerle, C. Neumann, S. Zschau et al., “Impact of fasting and postprandial glycaemia on overall glyemic control in type 2 diabetes Importance of postprandial glycaemia to achieve target HbA1c levels,” *Diabetes Research and Clinical Practice*, vol. 77, no. 2, pp. 280–285, 2007.
[9] R. Peter, S. D. Luzio, G. Dunseath, V. Pauvaday, N. Mustafa, and D. R. Owens, "Relationship between HbA1c and indices of glucose tolerance derived from a standardized meal test in newly diagnosed treatment naive subjects with type 2 diabetes," Diabetic Medicine, vol. 23, no. 9, pp. 990–995, 2006.

[10] W. H. Li, X. H. Xiao, Q. Sun, G. H. Yang, and H. Wang, "Relationship between hemoglobin A1c and blood glucose throughout the day in well-glycemic-controlled medical nutrition therapy alone type 2 diabetic patients," Chinese Medical Sciences Journal = Chung-Kuo I Hsueh K'o Hsueh Tsai Chi/Chinese Academy of Medical Sciences, vol. 21, no. 2, pp. 90–94, 2006.

[11] R. Peter, G. Dunseath, S. D. Luzio, R. Chudleigh, S. R. Choudhury, and D. R. Owens, "Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA1cin subjects with type 2 diabetes," Diabetic Medicine, vol. 26, no. 10, pp. 974–980, 2009.

[12] K. Kikuchi, U. Nezu, J. Shirakawa et al., "Correlations of fasting and postprandial blood glucose increments to the overall diurnal hyperglycemic status in type 2 diabetic patients: variations with levels of HbA1c," Endocrine Journal, vol. 57, no. 3, pp. 259–266, 2010.

[13] M. Riddle, G. Umpierrez, A. DiGenio, R. Zhou, and J. Rosenstock, "Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes," Diabetes Care, vol. 34, no. 12, pp. 2508–2514, 2011.

[14] J.-S. Wang, S.-T. Tu, I.-T. Lee et al., "Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring," Diabetes/Metabolism Research and Reviews, vol. 27, no. 1, pp. 79–84, 2011.

[15] K. G. M. M. Alberti, P. Z. Zimmet, and WHO Consultation, "Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation," Diabetic Medicine, vol. 15, no. 7, pp. 539–553, 1998.

[16] J. Mastrototaro, "The MiniMed continuous glucose monitoring system (CGMS)," Journal of Pediatric Endocrinology & Metabolism: JPEM, vol. 12, no. 3, pp. 751–758, 1999.

[17] E. B. Ketema and K. T. Kibret, "Correlation of fasting and postprandial plasma glucose with HbA1c in assessing glycemic control; systematic review and meta-analysis," Archives of Public Health/Archives Belges de Sante Publique, vol. 73, p. 43, 2015.

[18] F. Cavalot, A. Pagliarino, M. Valle et al., "Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga diabetes study," Diabetes Care, vol. 34, no. 10, pp. 2237–2243, 2011.

[19] X. Kang, C. Wang, D. Chen et al., "Contributions of basal glucose and postprandial glucose concentrations to hemoglobin A1c in the newly diagnosed patients with type 2 diabetes-the preliminary study," Diabetes Technology & Therapeutics, vol. 17, no. 7, pp. 445–448, 2015.

[20] L. Monnier, C. Colette, S. Dejager, and D. Owens, "Residual dysglycemia when at target HbA1c of 7% (53 mmol/mol) in persons with type 2 diabetes," Diabetes Research and Clinical Practice, vol. 104, no. 3, pp. 370–375, 2014.